FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to a composition for the treatment or prevention of myocardial damage or heart failure. The pharmaceutical composition for the treatment or prevention of myocardial damage or heart failure contains following components: phenolic acids of 2-20 parts by weight; flavonoids of 0.5-5 parts by weight; tanshinones of 0.005-0.5 part by weight; saponins of 5-20 parts by weight; essential oils of 10-18 parts by weight. In this case, phenolic acids include Danshen, protocatechuic aldehyde, salvianolic acid T, salvianolic acid U, salvianolic acid D, salvianolic acid G, rosemary acid, lithospermic acid, salvianolic acid B, salvianolic acid A, isosalvianolic acid C; flavonoids include calicosin-7-glucoside, ononin, calicosin, formononetin; tanshinones include dihydrotanshinone I, cryptotanshinone, tanshinone I, tanshinone IIA; saponins include notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, astragaloside, ginsenoside Rd; and essential oils include trans-nerolidol, nerolidol oxide. The use of the above-described pharmaceutical composition for the production of a drug for improvement of a condition in myocardial damage or a drug for the treatment or prevention of heart failure is also described. A pharmaceutical drug for the treatment or prevention of myocardial damage or heart failure contains the above-described pharmaceutical composition, where the pharmaceutical composition is 0.1~99.9 wt.% of the pharmaceutical drug, and the rest is a pharmaceutically acceptable carrier (carriers). A method for the treatment or prevention of myocardial damage or heart failure includes administration of effective amount of the above-described pharmaceutical composition or pharmaceutical drug to a subject, which has myocardial damage and/or heart failure or the risk of their presence.
EFFECT: above-described composition and drug have synergetic activity relatively to the treatment or prevention of myocardial damage or heart failure.
26 cl, 6 dwg, 12 tbl, 3 ex
Authors
Dates
2022-12-20—Published
2019-04-04—Filed